

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Ocular Oncology and Oculoplasty

Journal homepage: <https://ijooo.org/>

## Editorial

# PAX6 gene and its role in ocular malformations

Rajendra Prakash Maurya<sup>1,\*</sup>, Rajnikant Mishra<sup>2</sup>, Sneha Gupta<sup>1</sup>

<sup>1</sup>Regional Institute of Ophthalmology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

<sup>2</sup>Dept. of Zoology, Institute of Sciences Banaras Hindu University, Varanasi, Uttar Pradesh, India



## ARTICLE INFO

### Article history:

Received 20-10-2023

Accepted 02-11-2023

Available online 06-11-2023

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

PAX 6 gene is located on short arm of chromosome 11 on locus 11p13.<sup>1</sup> Human PAX6 protein consists of 422 amino acids residues containing two DNA binding domains, a paired domain (128 AA) and homeobox domain (61 AA). The transactivation domain is Proline-Serine-Threonine (PST) rich. This gene is expressed throughout embryogenesis in late gastrula stage in the region of anterior neural plate, forebrain, all eye structures, ventral part of spinal cord and pancreas.

It is one of regulator of regulators and multi-functional proteins. Regulation of PAX6 gene is a complex process. There are four identified transcription start sites corresponding to promoter P0, P1, P $\alpha$  and P4. From two promoter P0 and P1 two different variants of transcription factors are formed which encode same proteins. From promoter P $\alpha$  and P4 same truncated isoform without the paired domain is expressed.<sup>2</sup> This complex pattern of expression of transcriptional variants of PAX6 gene is regulated by several tissue specific regulatory factors.<sup>3</sup>

Numerous regulatory microRNAs are able to regulate expression of PAX6 gene at transcriptional level. It is involved in corneal morphogenesis,<sup>4</sup> differentiation of various neurons, mesenchymal stem cells, tumor development as in retinoblastoma, glioblastoma etc. in which it acts as a tumor suppressor gene.<sup>5</sup> Activity of PAX6 gene or protein can be regulated by post translational

modification mainly by phosphorylation through kinases.<sup>6</sup>

Regulated PAX6 gene expression provides necessary levels and ratio of expressed transcription variants which play key role in development of eye and central nervous system.<sup>7</sup> PAX6 gene has important role in organogenesis which control the specification and differentiation of cells of different origin. It also plays important role in maintaining multipotent state of several types of progenitor cells (neuronal retina, pigment epithelium of retina, iris and ciliary body, cortex and some structures of brain) and their proliferation. It was seen that the homeodomain regulates cell proliferation while paired domain regulate cell differentiation. It regulates expression of specific transcription factors, cell line differentiation regulators and act as both activator and suppressor of transcription and control terminal differentiation of certain ocular tissues like secondary lens fibers, smooth muscle of sphincter in iris, etc.<sup>8</sup> PAX6 also helps in maintaining stem cell pool in lens epithelium, corneal limb, pigment epithelium, ciliary body and iris.<sup>9</sup>

These mutations are generally iatrogenic (96%) with some variants (4%) having whole gene deletions. Most common iatrogenic mutations have variable penetrance and expressivity. Mutations are either nonsense, frame shift, missense or located at splice sites and C-terminal extension.<sup>10</sup> Introduction of a premature termination codon is most common mutation which lead to termination of translation. These patients tend to present classical aniridia

\* Corresponding author.

E-mail address: [mauryarp\\_bhu@yahoo.com](mailto:mauryarp_bhu@yahoo.com) (R. P. Maurya).

phenotype.<sup>11</sup> In missense variants, it is seen that they present with milder atypical phenotypes sometimes without iris defects but with defects like microphthalmia, optic nerve anomalies, coloboma, isolated foveal hypoplasia and anterior segment dysgenesis.<sup>12,13</sup> Chromosomal rearrangements like deletions, duplications, translocation, inversion and large deletions that included PAX6 and other neighboring genes like WT1 result in multisystem disease such as WAGR syndrome characterized by Wilms tumor, aniridia, genitourinary anomalies and mental retardation.<sup>14</sup> Most PAX6 genes causing aniridia are heterozygous, sporadic (two- third) or familial (one- third) in an autosomal dominant pattern.<sup>15</sup>

Aniridia is a pan ocular disorder which involves defect in formation of iris, cornea, lens, fovea and optic nerve bilaterally.<sup>13,16</sup> It comprises incomplete or partial iris hypoplasia with nystagmus and foveal hypoplasia with latter being main cause of diminution of vision since birth. MAC (microphthalmia, anophthalmia and coloboma) is a group of developmental eye disorder which is characterized by decrease or absence of ocular globe due to mutation of more than 90 genes. Anophthalmia is associated with homozygous PAX6 variant associated with biallelic loss of function of gene. Gillespie syndrome and Peter's anomaly (anterior segment dysgenesis) are also associated with PAX6 mutation.

## 1. Conflict of Interest

None.

## 2. Source of Funding

None.

## References

1. Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T, et al. Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. *Cell*. 1991;67(6):1059–74.
2. Shaham O, Menuchin Y, Farhy C, Ashery-Padan R. Pax6: a multi-level regulator of ocular development. *Prog Retin Eye Res*. 2012;31(5):351–76. doi:10.1016/j.preteyeres.2012.04.002.
3. Shukla S, Mishra R. Predictions on impact of missense mutations on structure function relationship of PAX6 and its alternatively spliced isoform PAX6(5a). *Interdiscip Sci*. 2012;4(1):54–73.
4. Shalom-Feuerstein R, Serror L, Divonne S, LDF, Aberdam E, Camargo L, Damour O, et al. Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specification. *Stem Cells*. 2012;30(5):898–909.
5. Meng Y, Zou Q, Liu T, Cai X, Huang Y, Pan J, et al. microRNA-335 inhibits proliferation, cell-cycle progression, colony formation, and invasion via targeting PAX6 in breast cancer cells. *Mol Med Rep*. 2015;11(1):379–85.
6. Simpson TI, Price DJ. Pax6; a pleiotropic player in development. *Bioessays*. 2002;24(11):1041–51.
7. Manuel MN, Mi D, Mason JO, Price DJ. Regulation of cerebral cortical neurogenesis by the Pax6 transcription factor. *Front Cell Neurosci*. 2015;9:70. doi:10.3389/fncel.2015.00070.
8. Tzoulaki I, White IM, Hanson I. PAX6 mutations: Genotype-phenotype correlations. *BMC Genet*. 2005;6:27. doi:10.1186/1471-2156-6-27.
9. Moosajee M, Hingorani M, Moore A. PAX6-Related Aniridia. Adam M, Ardinger H, Pagon R, Wallace S, Bean L, Stephens K, et al., editors. Seattle, DC, USA: GeneReviews((R)) University of Washington; 2018.
10. Azuma N, Nishina S, Yanagisawa H, Okuyama T, Yamada M. PAX6 missense mutation in isolated foveal hypoplasia. *Nat Genet*. 1996;13(2):141–2.
11. Azuma N, Yamaguchi Y, Handa H, Tadokoro K, Asaka A, Kawase E, et al. Mutations of the PAX6 Gene Detected in Patients with a Variety of Optic-Nerve Malformations. *Am J Hum Genet*. 2003;72(6):1565–70.
12. Robinson DO, Howarth RJ, Williamson KA, Van Heyningen V, Beal SJ, Crolla J, et al. Genetic analysis of chromosome 11p13 and the PAX6 gene in a series of 125 cases referred with aniridia. *Am J Med Genet Part A*. 2008;146A(5):558–69.
13. Shukla S, Mishra R. Level of hydrogen peroxide affects expression and sub-cellular localization of Pax6. *Mol Biol Rep*. 2018;45(4):533–40.
14. Hingorani M, Williamson KA, Moore AT, Van Heyningen V. Detailed ophthalmologic evaluation of 43 individuals with PAX6 mutations. *Investig Ophthalmol Vis Sci*. 2009;50:2581–90.
15. Yokoi T, Nishina S, Fukami M, Ogata T, Hosono K, Hotta Y, et al. Genotype-phenotype correlation of PAX6 gene mutations in aniridia. *Hum Genome Var*. 2016;3:15052. doi:10.1038/hgv.2015.52.
16. Shukla S, Mishra R. Functional analysis of missense mutations G36A and G51A in PAX6, and PAX6(5a) causing ocular anomalies. *Exp Eye Res*. 2011;93(1):40–9.

## Author biography



**Rajendra Prakash Maurya**, Associate Professor  
Regional Institute-Ophthalmology  
Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India  
Email id : mauryarp\_bhu@yahoo.com  
<https://orcid.org/0000-0001-9343-6003>



**Rajnikant Mishra**, Professor (Ph.D, FIANS, FZSI)

**Sneha Gupta**, Junior Resident (MBBS)

**Cite this article:** Maurya RP, Mishra R, Gupta S. PAX6 gene and its role in ocular malformations. *IP Int J Ocul Oncol Oculoplasty* 2023;9(3):111-112.